Abstract
Stroke is the most feared complication of atrial fibrillation but for over fifty years there has been no simple, effective preventative alternative to warfarin. The development of new risk algorithms such as CHADSVASC has resulted in more patients being recommended anticoagulation therapy. Fixed dose oral anticoagulation is a landmark in drug development for atrial fibrillation. The differences between the drugs are discussed and the trial data examined. As we enter this new frontier of therapy, there is no doubt that these drugs will transform the delivery of anticoagulation for patients with atrial fibrillation.
Keywords: Atrial fibrillation, apixaban, dabigatran, direct thrombin inhibitors, edoxaban, factor Xa, thromboembolism, warfarin, rivoroxaban.
Cardiovascular & Hematological Disorders-Drug Targets
Title:Atrial Fibrillation – New Frontiers in Anticoagulation
Volume: 14 Issue: 1
Author(s): Ranji Thomas, Pierre Le Page and Andrew R.J. Mitchell
Affiliation:
Keywords: Atrial fibrillation, apixaban, dabigatran, direct thrombin inhibitors, edoxaban, factor Xa, thromboembolism, warfarin, rivoroxaban.
Abstract: Stroke is the most feared complication of atrial fibrillation but for over fifty years there has been no simple, effective preventative alternative to warfarin. The development of new risk algorithms such as CHADSVASC has resulted in more patients being recommended anticoagulation therapy. Fixed dose oral anticoagulation is a landmark in drug development for atrial fibrillation. The differences between the drugs are discussed and the trial data examined. As we enter this new frontier of therapy, there is no doubt that these drugs will transform the delivery of anticoagulation for patients with atrial fibrillation.
Export Options
About this article
Cite this article as:
Thomas Ranji, Page Le Pierre and Mitchell R.J. Andrew, Atrial Fibrillation – New Frontiers in Anticoagulation, Cardiovascular & Hematological Disorders-Drug Targets 2014; 14 (1) . https://dx.doi.org/10.2174/1871529X1401140724094846
DOI https://dx.doi.org/10.2174/1871529X1401140724094846 |
Print ISSN 1871-529X |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-4063 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Anti-Oxidative Stress and Beyond: Multiple Functions of the Protein Glutathionylation
Protein & Peptide Letters Triglycerides and Cardiovascular Risk
Current Cardiology Reviews Implications of Pharmacogenetics for Oral Anticoagulants Metabolism
Current Drug Metabolism Mobile Phone Based Biomedical Imaging Technology: A Newly Emerging Area
Recent Patents on Biomedical Engineering (Discontinued) Resistant Hypertension in the Elderly-Second Line Treatments: Aldosterone Antagonists, Central Alpha-Agonist Agents, Alpha-Adrenergic Receptor Blockers, Direct Vasodilators, and Exogenous Nitric Oxide Donors
Cardiovascular & Hematological Agents in Medicinal Chemistry Editorial (Thematic Issue: Frontiers in Atherosclerosis, Heart Disease and Diabetes)
Cardiovascular & Hematological Disorders-Drug Targets Anesthetic-induced Myocardial Conditioning: Molecular Fundamentals and Scope
Current Medicinal Chemistry Non Alcoholic Fatty Liver: Epidemiology and Natural History
Reviews on Recent Clinical Trials New Approaches to Raising the HDL Cholesterol Level
Mini-Reviews in Medicinal Chemistry Ischemic Strokes in Congenital Bleeding Disorders: Comparison with Myocardial Infarction and other Acute Coronary Syndromes
Cardiovascular & Hematological Disorders-Drug Targets Atheromatosis Extent in Coronary Artery Disease is not Correlated with Apolipoprotein-E Polymorphism and its Plasma Levels, but Associated with Cognitive Decline
Current Alzheimer Research Dihydrobenzo[1,4]oxathiine: A Multi-Potent Pharmacophoric Heterocyclic Nucleus
Current Medicinal Chemistry Drugs for the Treatment of Hypercholesterolemia and their Benefits Beyond Cholesterol Lowering to Prevent Vascular Disease
Vascular Disease Prevention (Discontinued) Potential Use of Dendritic Cells for Anti-Atherosclerotic Therapy
Current Pharmaceutical Design Lipid-lowering Drug Therapy in Elderly Patients
Current Pharmaceutical Design Cerebrovascular Endothelin Receptor Upregulation in Cerebral Ischemia
Current Vascular Pharmacology The Need for Diagnostic Criteria in Systemic Vasculitis
Current Immunology Reviews (Discontinued) The Role of Autophagy in the Pathogenesis of Ischemic Stroke
Current Neuropharmacology Antioxidants in the Practice of Medicine; What Should the Clinician Know?
Cardiovascular & Hematological Disorders-Drug Targets Main Anti-tumor Angiogenesis Agents Isolated From Chinese Herbal Medicines
Mini-Reviews in Medicinal Chemistry